Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Raouf Hilal

Gastroenterology Maitland, FL Medical Doctor

NPI 1427161793 CMS profile 246479

740 S Concourse Pkwy, Suite 200, Maitland, FL 32751

Open in the dashboard

General payments

$13,099

719 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Raouf Hilal of Maitland, FL is reported in the CMS Open Payments database as having received $13,099 across 719 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,190 109
2024 General $2,488 120
2023 General $2,453 120
2022 General $1,753 108
2021 General $1,433 93
2020 General $985 56
2019 General $1,798 113

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Raouf Hilal
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Raouf Hilal were reported at $2,190. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Raouf Hilal Gastroenterology median Middle half National median
2019 $1,798 $417 $126–$1,100 $163
2020 $985 $224 $74–$624 $114
2021 $1,433 $352 $106–$1,054 $132
2022 $1,753 $448 $129–$1,270 $149
2023 $2,453 $533 $150–$1,390 $160
2024 $2,488 $605 $160–$1,606 $164
2025 $2,190 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $4,117 258 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,459 90 payments
  3. Celgene Corporation $849 41 payments
  4. Pfizer Inc. $827 46 payments
  5. Phathom Pharmaceuticals, Inc. $757 12 payments
  6. Gilead Sciences, Inc. $544 38 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $436 23 payments
  8. Madrigal Pharmaceuticals $420 15 payments
  9. Aimmune Therapeutics, Inc. $396 20 payments
  10. Janssen Biotech, Inc. $370 20 payments
  11. Other $2,924 156 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $13,058 717 payments
  2. Consulting Fee $24 1 payment
  3. Education $17 1 payment
Products named General payments · program years 2019–2025
  1. XIFAXAN $1,361 78 payments
  2. LINZESS $967 71 payments
  3. RINVOQ $917 39 payments
  4. CREON $857 71 payments
  5. ZEPOSIA $825 40 payments
  6. ZENPEP $761 43 payments
  7. HUMIRA $650 49 payments
  8. SKYRIZI $612 42 payments
  9. XELJANZ $587 32 payments
  10. MAVYRET $544 31 payments
  11. Other $7,304 373 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 50 drugs

Part D claims

3,327

Median for Internal Medicine: 777

Drug cost

$2,576,307

Median for Internal Medicine: $73,373

Branded share of claims

41.1%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gattex Teduglutide Brand 12 $1,112,555
Creon Lipase/Protease/Amylase Brand 78 $360,291
Epclusa Sofosbuvir/Velpatasvir Brand 11 $267,441
Linzess Linaclotide Brand 240 $180,627
Zenpep Lipase/Protease/Amylase Brand 25 $173,909
Entyvio Vedolizumab Brand 16 $135,114
Xifaxan Rifaximin Brand 37 $112,393
Humira(Cf) Pen Adalimumab Brand 13 $85,757
Voquezna Vonoprazan Fumarate Brand 39 $24,631
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 271 $17,293

The 10 drugs with the highest cost, of 50 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 21 billing codes

Paid by Medicare

$85,345

Medicare's payments for the services billed

Medicare patients

385

Average age 72

Services billed

796

231 women, 154 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 50%
Ischemic heart disease 40%
Diabetes 37%
Depression 26%
Chronic kidney disease 25%
Osteoporosis 20%
COPD 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 29 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $543
$543 39 —
RINVOQ
  • AbbVie, Inc. $177
$177 — —
SKYRIZI
  • AbbVie, Inc. $169
$169 — —
ZENPEP
  • AIMMUNE THERAPEUTICS, INC. $158
$158 25 —
VELSIPITY
  • PFIZER INC. $153
$153 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 29 with Patron

Records

719 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record